Allarity Therapeutics(ALLR) - 2023 Q4 - Annual Results

Exhibit 99.1 Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update - Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graf , Ph.D., former Eli Lilly Executive, as Executive Advisor - Reduced Net Loss from Operations by 50% and Reduced Net Loss by 26% - Announced Data in December 2023 from Advanced Ovarian Cancer Phase 2 Stenoparib Study Showing Significant Clinical Benefit Boston (March 8, 2024) — Allarity Therapeutics, Inc. ...